

## PHARMACY COVERAGE GUIDELINE

### ORGOVYX™ (relugolix) Generic Equivalent (if available)

---

#### **This Pharmacy Coverage Guideline (PCG):**

- Provides information about the reasons, basis, and information sources we use for coverage decisions
- Is not an opinion that a drug (collectively “Service”) is clinically appropriate or inappropriate for a patient
- Is not a substitute for a provider’s judgment (Provider and patient are responsible for all decisions about appropriateness of care)
- Is subject to all provisions e.g. (benefit coverage, limits, and exclusions) in the member’s benefit plan; and
- Is subject to change as new information becomes available.

#### **Scope**

- This PCG applies to Commercial and Marketplace plans
- This PCG does not apply to the Federal Employee Program, Medicare Advantage, Medicaid or members of out-of-state Blue Cross and/or Blue Shield Plans

#### **Instructions & Guidance**

- To determine whether a member is eligible for the Service, read the entire PCG.
  - This PCG is used for FDA approved indications including, but not limited to, a diagnosis and/or treatment with dosing, frequency, and duration.
  - Use of a drug outside the FDA approved guidelines, refer to the appropriate Off-Label Use policy.
  - The “**Criteria**” section outlines the factors and information we use to decide if the Service is medically necessary as defined in the Member’s benefit plan.
  - The “**Description**” section describes the Service.
  - The “**Definition**” section defines certain words, terms or items within the policy and may include tables and charts.
  - The “**Resources**” section lists the information and materials we considered in developing this PCG
  - **We do not accept patient use of samples as evidence of an initial course of treatment, justification for continuation of therapy, or evidence of adequate trial and failure.**
  - Information about medications that require prior authorization is available at [www.azblue.com/pharmacy](http://www.azblue.com/pharmacy). You must fully complete the [request form](#) and provide chart notes, lab workup and any other supporting documentation. The prescribing provider must sign the form. Fax the form to BCBSAZ Pharmacy Management at (602) 864-3126 or email it to [Pharmacyprecert@azblue.com](mailto:Pharmacyprecert@azblue.com).
- 

#### **Criteria:**

- **Criteria for initial therapy:** Orgovyx (relugolix) and/or generic equivalent (if available) is considered **medically necessary** and will be approved when **ALL** of the following criteria are met:
  1. Prescriber is a physician specializing in the patient’s diagnosis or is in consultation with an Oncologist or Urologist
  2. Individual is 18 years of age or older
  3. Individual has a confirmed diagnosis of **ONE** of the following:
    - a. Advanced prostate cancer

## PHARMACY COVERAGE GUIDELINE

### ORGOVYX™ (relugolix) Generic Equivalent (if available)

---

- b. Other request for a specific oncologic direct treatment use that is found and listed in the National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1 and 2A
4. Individual is a candidate for at least 1 year of continuous androgen deprivation therapy for the management of androgen-sensitive advanced prostate cancer with **ONE** of the following:
  - a. Evidence of biochemical (PSA) or clinical relapse following local primary intervention with curative intent, such as surgery, radiation therapy, cryotherapy, or high-frequency ultrasound and not a candidate for salvage treatment by surgery
  - b. Newly diagnosed androgen-sensitive metastatic disease
  - c. Advanced localized disease unlikely to be cured by local primary intervention with either surgery or radiation with curative intent
5. Individual has failure, contraindication per FDA label, or intolerance, or not a candidate for leuprolide acetate depot
6. **If available:** Individual has failure after adequate trial, contraindication per FDA label, intolerance, or is not a candidate for a **generic equivalent** [Note: Failure, contraindication or intolerance to the generic should be reported to the FDA] ([see Definitions section](#))
7. Individual has received and completed **ALL** the following **baseline tests** before initiation of treatment and with continued monitoring of the individual as clinically appropriate:
  - a. Baseline serum testosterone of  $\geq 150$  ng/dL
  - b. Baseline serum PSA concentration of  $> 2.0$  ng/mL (2.0 microgram [ $\mu\text{g}$ ]/L), or, when applicable, post radical prostatectomy of  $> 0.2$  ng/mL (0.2  $\mu\text{g}$ /L) or post radiotherapy, cryotherapy, or high frequency ultrasound  $> 2.0$  ng/mL (2.0  $\mu\text{g}$ /L) above the post interventional nadir
  - c. Eastern Cooperative Oncology Group performance status of 0 or 1

**Initial approval duration:** 6 months

- **Criteria for continuation of coverage (renewal request):** Orgovyx (relugolix) and/or generic equivalent (if available) is considered **medically necessary** and will be approved when **ALL** the following criteria are met (**samples are not considered for continuation of therapy**):
1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with an Oncologist or Urologist
  2. Individual's condition has responded while on therapy with response defined as the following:
    - a. Achieved and is maintaining serum testosterone suppression to medical castration levels (less than 50 ng/dL)
    - b. No disease progression
  3. Individual has been adherent with the medication
  4. **If available:** Individual has failure after adequate trial, contraindication per FDA label, intolerance, or is not a candidate for a **generic equivalent** [Note: Failure, contraindication or intolerance to the generic should be reported to the FDA] ([see Definitions section](#))

ORIGINAL EFFECTIVE DATE: 05/20/2021 | ARCHIVE DATE: | LAST REVIEW DATE: 05/16/2024 | LAST CRITERIA REVISION DATE: 05/16/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

## PHARMACY COVERAGE GUIDELINE

### ORGOVYX™ (relugolix) Generic Equivalent (if available)

---

5. Individual has not developed any significant adverse drug effects that may exclude continued use such as:
  - a. QT/QTc interval prolongation
  - b. Severe hypersensitivity reaction such as pharyngeal edema or angioedema

**Renewal duration:** 12 months

- Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. **Off-Label Use of Non-Cancer Medications**
  2. **Off-Label Use of Cancer Medications**
- 

#### **Description:**

Orgovyx (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer. GnRH receptor antagonists competitively bind to pituitary GnRH receptors, in so doing, reduce the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and consequently testosterone.

---

#### **Definitions:**

U.S. Food and Drug Administration (FDA) MedWatch Forms for FDA Safety Reporting  
[MedWatch Forms for FDA Safety Reporting | FDA](#)

**Gonadotropin-releasing hormone (GnRH) analogs or agonists:** (Also referred to as luteinizing hormone releasing hormone (LHRH) agonists or analogs)

Zoladex (goserelin acetate) subcutaneous implant  
Vantas (histrelin acetate) subcutaneous implant  
Eligard (leuprolide acetate) subcutaneous injection  
Lupron Depot (leuprolide acetate) intramuscular injection  
Trelstar (triptorelin pamoate) intramuscular injection

#### **Gonadotropin-releasing hormone antagonist:**

Firmagon (dagarelix) subcutaneous injection  
Orgovyx (relugolix)

**Antiandrogens, oral:** to maintain castrate serum levels of testosterone (< 50 ng/dL)

Zytiga (abiraterone acetate)  
Erleada (apalutamide)

**PHARMACY COVERAGE GUIDELINE**

**ORGOVYX™ (relugolix)  
Generic Equivalent (if available)**

- Casodex (bicalutamide)
- Nubequa (darolutamide)
- Xtandi (enzalutamide)
- Flutamide
- Nilandron (nilutamide)

**ECOG Performance status:**

Eastern Co-operative Oncology Group (ECOG) Performance Status	
Grade	ECOG description
0	Fully active, able to carry on all pre-disease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work
2	Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours
3	Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4	Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
5	Dead

Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982

**NCCN recommendation definitions:**

Category 1:

Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A:

Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B:

Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3:

Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate

**Resources:**

Orgovyx (relugolix) product information, revised by Sumitomo Pharma America, Inc. 01-2024. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed April 16, 2024.

Dawson NA. Overview of the systemic treatment for recurrent or metastatic castration-sensitive prostate cancer In: UpToDate, Lee WR, Richie JR, Vora SR (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through March 2024. Topic last updated January 10, 2024. Accessed April 16, 2024.

Lee RJ, Smith MR. Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer. In: UpToDate, Lee WR, Richie JR, Vora SR (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through March 2024. Topic last updated November 16, 2023. Accessed April 16, 2024

Dawson NA, Leger P. Overview of the treatment of castration-resistant prostate cancer (CRPC). In: UpToDate, Lee WR, Richie JR, Sartor AO, Vora SR (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through March 2024. Topic last updated October 05, 2023. Accessed April 16, 2024.

ORIGINAL EFFECTIVE DATE: 05/20/2021 | ARCHIVE DATE: | LAST REVIEW DATE: 05/16/2024 | LAST CRITERIA REVISION DATE: 05/16/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.



An Independent Licensee of the Blue Cross Blue Shield Association

## PHARMACY COVERAGE GUIDELINE

### **ORGOVYX™ (relugolix) Generic Equivalent (if available)**

---

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate Cancer Version 3.2024 – Updated March 08, 2024. Available at <https://www.nccn.org>. Accessed April 16, 2024.

Shore ND, Saad F, Cookson MS, et al: Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. NEJM 2020; 382 Jun 4:2187-2196. Accessed March 03, 2021. Re-evaluated April 16, 2024.

Off Label Use of Cancer Medications: A.R.S. §§ 20-826(R) & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions.

ORIGINAL EFFECTIVE DATE: 05/20/2021 | ARCHIVE DATE: | LAST REVIEW DATE: 05/16/2024 | LAST CRITERIA REVISION DATE: 05/16/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.